Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI

Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI

The recent first global approval of delafloxacin has been reviewed in detail in the First Global Approval report in Adis journal Drugs[1], based on the development milestones tracked in AdisInsight.[2] Continue reading “Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI”

Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease; immune-stimulation brings hope in bladder cancer

Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease;  immune-stimulation brings hope in bladder cancer

The recent first global approval of durvalumab has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1] based on the development milestones tracked in AdisInsight.[2] Continue reading “Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease; immune-stimulation brings hope in bladder cancer”

Abaloparatide (Tymlos™): First Global Approval – bone formation fends off fragility fractures in postmenopausal women with high-risk osteoporosis

Abaloparatide (Tymlos™): First Global Approval – bone formation fends off fragility fractures in postmenopausal women with high-risk osteoporosis

The recent first global approval of abaloparatide has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Abaloparatide (Tymlos™): First Global Approval – bone formation fends off fragility fractures in postmenopausal women with high-risk osteoporosis”

Midostaurin (Rydapt®): First Global Approval – Double Trap shots on target for FLT3-mutated AML and Advanced SM

Midostaurin (Rydapt®): First Global Approval – Double Trap shots on target for FLT3-mutated AML and Advanced SM

The recent first (double) global approval of midostaurin has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Midostaurin (Rydapt®): First Global Approval – Double Trap shots on target for FLT3-mutated AML and Advanced SM”

Brigatinib (ALUNBRIG™): First Global Approval – resistance is futile in the battle against metastatic NSCLC

Brigatinib (ALUNBRIG™): First Global Approval –  resistance is futile in the battle against metastatic NSCLC

The recent first global approval of brigatinib has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Brigatinib (ALUNBRIG™): First Global Approval – resistance is futile in the battle against metastatic NSCLC”